Bridge Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-4,527
Closed -$507K 108
2021
Q4
$507K Sell
4,527
-184
-4% -$22.2K 0.23% 65
2021
Q3
$592K Buy
4,711
+1,086
+30% +$140K 0.29% 49
2021
Q2
$491K Buy
+3,625
New +$477K 0.25% 55

Other funds holding XBI

Bridge Advisory's XBI Position: Q1 2022 in Review

Bridge Advisory sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 4,527 shares — an estimated $507K sold.

Bridge Advisory first reported a position in XBI in Q2 2021 and held it in 3 quarters. The position peaked at $592K in Q3 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

  • Bridge Advisory reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
  • Bridge Advisory sold 4,527 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $507K.
  • Bridge Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 3 quarters.
  • Bridge Advisory's State Street SPDR S&P Biotech ETF position peaked at $592K in Q3 2021.
  • 703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Bridge Advisory's 13F filing for Q1 2022, filed 18 Apr 2022.